Register now!

Patients all over the world should benefit from the achievements of predictive medicine and the introduction of in silico clinical trials (ISCTs), which promise the accelerated and safe introduction of new products such as medical devices or pharmaceuticals to the market place. These concepts cannot be developed by academics or in industry alone, and ultimately they need to be accepted by regulatory agencies around the world. When regulators accept simulation augmented submissions, and agree upon a common model credibility assessment philosophy will patients benefit from the utilization of in silico medicine. 

The objective of the Avicenna Alliance International Working Group is the promotion of the benefits of predictive medicine and ISCTs through the global connections of experts from academia, industry, and regulatory agencies. Together we will work on developing objective standards, increasing confidence in in silico methods and their acceptance in support of regulatory approval process.

Avicenna Alliance news

Don’t miss the deadline to submit abstracts to Virtual Physiological Human Conference on In Silico Medicine

The deadline for submitting abstracts for the Virtual Physiological Human Conference 2018...

find out more ›

Avicenna Alliance continues to grow by welcoming Cipla among its members

The latest company to join Avicenna Alliance is the pharmaceutical company Cipla. The Alliance is happy to welcome this...

find out more ›

EFGCP & Avicenna Alliance Webinar on Modelling a Policy Framework for In Silico Medicine

No matter how predictive or advanced a computer model is, it is commercially useless if it is not accepted by...

find out more ›

Show all activites